Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.

ABSTRACT:

Objective

To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer.

Methods

A post-hoc analysis of the Japanese subgroup in the phase III, randomized, multinational ARCHES study (NCT02677896) was carried out. Patients with metastatic hormone-sensitive prostate cancer were randomized to receive enzalutamide or a placebo, plus androgen deprivation therapy, stratified by disease volume and prior docetaxel therapy. The primary end-point was radiographic progression-free survival. Secondary end-points included time to prostate-specific antigen progression and overall survival.

Results

Of 1150 patients, 92 Japanese patients were randomized to enzalutamide (n = 36) or a placebo (n 

SUBMITTER: Iguchi T 

PROVIDER: S-EPMC8360194 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature